Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. (June 2022)

• Record Type: Journal Article
• Authors: Hafliger, Emilie; Boccaccino, Alessandra; Lapeyre-Prost, Alexandra; Perret, Audrey; Gallois, Claire; Antista, Maria; Pilla, Lorenzo; Lecomte, Thierry; Scartozzi, Mario; Soularue, Emilie; Salvatore, Lisa; Bourgeois, Vincent; Salati, Massimiliano; Tougeron, David; Evesque, Ludovic; Vaillant, Jean-Nicolas; El-Khoury, Reem; Lonardi, Sara; Cremolini, Chiara; Taieb, Julien
• Is Part Of: European journal of cancer. Volume 168(2022)
• Page Start: 34
• Page End: 40
• Publication Date: 2022-06
• Subjects: Metastatic colon cancer -- BRAF V600E mutation -- Anti-EGFRs -- BRAF inhibitors; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.03.011
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background : Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). No data are available concerning the efficacy of BRAF inhibitors associated with anti-EGFRs (B + E) in patients previously treated with an anti-EGFR agent. Methods : We retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and overall survival (OS) were calculated from the start of treatment, and we reported objective response and disease control rates (ORR, DCR; RECIST V1.1). Results : Twenty-five BRAFm mCRC patients were enrolled. Prior to B + E treatment, 4/10/11 patients were treated with 1/2/> 2 previous treatment lines. Ten patients received previous panitumumab, 14 cetuximab, 1 both. Immediate progression with previous anti-EGFR was reported for 7 patients. Anti-BRAF was encorafenib for 21 patients, dabrafenib for 4 patients, with cetuximab for 24 patients and panitumumab for 1 patient. ORR was 40% (10 patients) and DCR was 80% (20 patients). Median PFS and OS were 4.8 months (95% CI, 4.01–7.95) and 10.1 months (95% CI, 7.75-NR). DCR amongst patients with previous primary resistance to anti-EGFR (N = 7) was 100%. Two patients discontinued B + E due to drug-related adverse event. Conclusions : Though in a limited retrospective series of patients, these results show the efficacy of the combination of anti-BRAF and anti-EGFRs in BRAFm mCRC patients previously treated with an anti-EGFR. The use of this combination should thus not be ruled out in this population with limited therapeutic options. Highlights: Series of 25 non anti-EGFR-naïve patients treated by anti-BRAF + anti-EGFR for a colorectal cancer. Median progression free survival and overall survival were 4.8 and 10.1 months. Ten out of 24 patients had an objective response rate. These results are very close to those reported in BEACON trial. This proves the efficacy of encorafenib + cetuximab in non-naïve anti-EGFR patients.